133 related articles for article (PubMed ID: 20510232)
1. How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?
Sokka T
Rheum Dis Clin North Am; 2010 May; 36(2):243-57. PubMed ID: 20510232
[TBL] [Abstract][Full Text] [Related]
2. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis.
Katchamart W; Bombardier C
J Rheumatol; 2010 Jul; 37(7):1411-5. PubMed ID: 20436069
[TBL] [Abstract][Full Text] [Related]
3. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.
Pincus T; Yazici Y; Bergman MJ
Rheum Dis Clin North Am; 2009 Nov; 35(4):773-8, viii. PubMed ID: 19962621
[TBL] [Abstract][Full Text] [Related]
4. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
Pincus T; Sokka T
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii32-ii39. PubMed ID: 15479869
[TBL] [Abstract][Full Text] [Related]
5. Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis.
Sokka T; Rannio T; Khan NA
Rheum Dis Clin North Am; 2012 May; 38(2):299-310. PubMed ID: 22819085
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of rheumatoid arthritis.
Sokka T
Curr Opin Rheumatol; 2009 May; 21(3):284-90. PubMed ID: 19342954
[TBL] [Abstract][Full Text] [Related]
7. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
8. Assessment and management of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
[TBL] [Abstract][Full Text] [Related]
9. Endpoints in rheumatoid arthritis.
Tugwell P; Boers M; Baker P; Wells G; Snider J
J Rheumatol Suppl; 1994 Oct; 42():2-8. PubMed ID: 7823314
[TBL] [Abstract][Full Text] [Related]
10. Patient-driven outcomes in rheumatoid arthritis.
Wells GA
J Rheumatol Suppl; 2009 Jun; 82():33-8. PubMed ID: 19509328
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
Yazici Y; Abramson SB
Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549
[TBL] [Abstract][Full Text] [Related]
12. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
13. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
Anderson JJ; Bolognese JA; Felson DT
Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
[TBL] [Abstract][Full Text] [Related]
14. Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care.
Castrejón I; Pincus T
Bull NYU Hosp Jt Dis; 2011; 69(2):104-10. PubMed ID: 22035388
[TBL] [Abstract][Full Text] [Related]
15. Improving the routine management of rheumatoid arthritis: the value of tight control.
Mease PJ
J Rheumatol; 2010 Aug; 37(8):1570-8. PubMed ID: 20595287
[TBL] [Abstract][Full Text] [Related]
16. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
Stone M; Fortin PR; Pacheco-Tena C; Inman RD
J Rheumatol; 2003 Oct; 30(10):2112-22. PubMed ID: 14528503
[TBL] [Abstract][Full Text] [Related]
17. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.
Wolfe F; Rasker JJ; Boers M; Wells GA; Michaud K
Arthritis Rheum; 2007 Aug; 57(6):935-42. PubMed ID: 17665487
[TBL] [Abstract][Full Text] [Related]
18. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis.
Harrison MJ; Tricker KJ; Davies L; Hassell A; Dawes P; Scott DL; Knight S; Davis M; Mulherin D; Symmons DP
J Rheumatol; 2005 Dec; 32(12):2330-6. PubMed ID: 16331758
[TBL] [Abstract][Full Text] [Related]
19. DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis.
van Riel PL; Fransen J
Arthritis Res Ther; 2005; 7(5):189-90. PubMed ID: 16207346
[TBL] [Abstract][Full Text] [Related]
20. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
